Eagle Pharmaceuticals Inc (EGRX) — Working Capital to Net Assets Ratio
Eagle Pharmaceuticals Inc (EGRX) has a Working Capital to Net Assets ratio of 39.9% as of June 2023. Working capital of $100.62 Million (current assets of $187.25 Million minus current liabilities of $86.63 Million) is measured against net assets of $252.04 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. See EGRX net asset quality index to measure how much of total assets are equity-financed.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Eagle Pharmaceuticals Inc Working Capital to Net Assets (2012–2022)
This chart shows how Eagle Pharmaceuticals Inc's Working Capital to Net Assets ratio has evolved across 11 annual periods from 2012 to 2022. As of June 2023, the ratio stands at 39.9%, reflecting working capital of $100.62 Million against net assets of $252.04 Million USD. Check EGRX goodwill-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Annual Working Capital to Net Assets for Eagle Pharmaceuticals Inc (2012–2022)
The table below presents the year-by-year Working Capital to Net Assets ratio for Eagle Pharmaceuticals Inc from 2012 to 2022, covering 11 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see Eagle Pharmaceuticals Inc market capitalisation.
| Year | WC/NA Ratio | Working Capital (USD) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2022 | 33.3% | $77.67 Million | $233.56 Million | $188.75 Million | $111.09 Million | ▼ -22.4 pp |
| 2021 | 55.7% | $98.23 Million | $176.45 Million | $172.61 Million | $74.38 Million | ▼ -13.1 pp |
| 2020 | 68.8% | $127.98 Million | $186.01 Million | $166.06 Million | $38.09 Million | ▼ -9.7 pp |
| 2019 | 78.5% | $140.63 Million | $179.17 Million | $179.45 Million | $38.82 Million | ▲ +1.3 pp |
| 2018 | 77.2% | $124.16 Million | $160.76 Million | $163.84 Million | $39.69 Million | ▼ -1.7 pp |
| 2017 | 78.9% | $141.40 Million | $179.14 Million | $188.70 Million | $47.30 Million | ▲ +33.4 pp |
| 2016 | 45.6% | $68.89 Million | $151.23 Million | $109.11 Million | $40.22 Million | ▼ -51.8 pp |
| 2015 | 97.4% | $88.00 Million | $90.34 Million | $122.26 Million | $34.26 Million | ▼ -1.4 pp |
| 2014 | 98.8% | $32.71 Million | $33.10 Million | $53.02 Million | $20.32 Million | ▼ -54.1 pp |
| 2013 | 152.9% | $3.14 Million | $2.05 Million | $17.48 Million | $14.34 Million | ▲ +53.6 pp |
| 2012 | 99.3% | $-12.02 Million | $-12.10 Million | $8.86 Million | $20.88 Million | — |